Testosterone Measured by 10 Immunoassays and by Isotope-Dilution Gas Chromatography–Mass Spectrometry in Sera from 116 Men, Women, and Children

Taieb, Julien; Mathian, B.; Millot, F.; Mc, Patricot; Mathieu, E; Queyrel, N.; Lacroix, Isabelle; Somma-Delpéro, Claude; Boudou, Philippe

doi:10.1373/49.8.1381

Cited by 570 publications

(382 citation statements)

References 41 publications

(26 reference statements)

Supporting

Mentioning

328

Contrasting

Unclassified

Order By: Relevance

“…We conducted a randomized double-blinded placebocontrolled study on aging men with low normal bioavailable testosterone levels, assessed using the gold standard testosterone analysis (Taieb et al 2003), and increased waist circumference. Testosterone therapy significantly increased LBM in men with bioavailable testosterone<7.3 nmol/l (Nielsen et al 2007).…”

Section: Discussionmentioning

confidence: 99%

Testosterone therapy increased muscle mass and lipid oxidation in aging men

Frederiksen

Højlund

Hougaard

et al. 2011

AGE

115

View full text Add to dashboard Cite

The indication for testosterone therapy in aging hypogonadal men without hypothalamic, pituitary, or testicular disease remains to be elucidated. The aim of this study was to investigate the effect of testosterone therapy on insulin sensitivity, substrate metabolism, body composition, and lipids in aging men with low normal bioavailable testosterone levels using a predefined cutoff level for bioavailable testosterone. A randomized, double-blinded, placebocontrolled study of testosterone treatment (gel) was done on 38 men, aged 60-78 years, with bioavailable testosterone <7.3 nmol/l and a waist circumference >94 cm. Insulin-stimulated glucose disposal (Rd) and substrate oxidation were assessed by euglycemic hyperinsulinemic clamps combined with indirect calorimetry. Lean body mass (LBM) and total fat mass (TFM) were measured by dual x-ray absorptiometry, and serum total testosterone was measured by tandem mass spectrometry. Bioavailable testosterone was calculated. Coefficients (b) represent the placebo-controlled mean effect of intervention. LBM (b=1.9 kg, p=0.003) increased while HDL-cholesterol (b=−0.12 mmol/l, p=0.043) and TFM decreased (b=−1.2 kg, p=0.038) in the testosterone group compared to placebo. Basal lipid oxidation (b=5.65 mg/min/m 2 , p=0.045) increased and basal glucose oxidation (b=−9.71 mg/min/m 2 , p = 0.046) decreased in response to testosterone therapy even when corrected for changes in LBM. No significant changes in insulin-stimulated Rd was observed (b=−0.01mg/min/m 2 , p=0.92). Testosterone therapy increased muscle mass and lipid oxidation in aging men with low normal bioavailable testosterone levels; however, our data did not support an effect of testosterone on whole-body insulin sensitivity using the euglycemic hyperinsulinemic clamp technique.

show abstract

Section: Discussionmentioning

confidence: 99%

Testosterone therapy increased muscle mass and lipid oxidation in aging men

Frederiksen

Højlund

Hougaard

et al. 2011

AGE

115

View full text Add to dashboard Cite

show abstract

“…Problems with steroid immunoassays have been reported for special patient groups, such as for female patients or preterm and acutely ill neonates (Herold and Fitzgerald, 2003;Taieb et al, 2003), or when analysing different media, e.g. saliva (Gröschl et al, 2001).…”

Section: Steroid Analysismentioning

confidence: 99%

“…While these assays may be valid in adult men, given their higher levels of hormone, these methods do not produce accurate results in children or females with lower levels of these steroids. Taieb et al (Taieb et al, 2003) show that none of the immunoassays tested was sufficiently reliable enough for the investigation of the low and very low testosterone concentrations expected in sera from children and women. These assays are therefore unlikely to be useful for diagnosis, follow-up of sexual differentiation, or for general use in pediatric surveys.…”

Section: Testosteronementioning

confidence: 99%

See 1 more Smart Citation

Steroid measurement with LC–MS/MS in pediatric endocrinology

Rauh

2009

Molecular and Cellular Endocrinology

View full text Add to dashboard Cite

Please cite this article as: Rauh, M., Steroid measurement with LC-MS/MS in pediatric endocrinology, Molecular and Cellular Endocrinology (2008), doi:10.1016/j.mce.2008 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…This sometimes is said more easily than done. Some laboratories provide excessively broad normal ranges for total testosterone, because many commercial direct assays are inaccurate [91] and because the general population includes women with asymptomatic mild androgen excess [43,49]. Direct assays of free testosterone are suspect; the most reliable compute free testosterone from total testosterone and sex hormone binding globulin [92].…”

Section: Determining the Presence Of Androgen Excessmentioning

confidence: 99%

Polycystic Ovary Syndrome in Adolescence

Driscoll

2003

Semin Reprod Med

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is a syndrome of variable combinations of menstrual irregularity, hirsutism or acne, and obesity. It can be diagnosed in adolescence and has early childhood antecedents. PCOS is the single most common endocrine cause of anovulatory infertility and a major risk factor for the metabolic syndrome and, in turn, development of type 2 diabetes mellitus (T2DM) in women. Thus, it appears that PCOS increases a woman's risk of developing cardiovascular disease. Therefore, identifying girls at risk for PCOS and implementing treatment early in the development of PCOS may be an effective means of preventing some of the long-term complications associated with this syndrome. This article reviews the definition, clinical features, diagnosis, and treatment of PCOS. Definition Classic polycystic ovary syndromeThe classic syndrome originally was described in 1935 by Stein and Leventhal as the association of amenorrhea with polycystic ovaries in women, of whom about two thirds were hirsute, and one half were obese [1]. The term PCOS was introduced upon recognition of a broader spectrum of clinical symptoms and ovarian histology, including stromal hyperplasia with multiple subcapsular follicles. Approximately two-thirds of patients with classic PCOS have hirsutism (or hirsutism equivalents, acne vulgaris or pattern alopecia), two-thirds have anovulatory symptoms (manifested as amenorrhea, oligomenorrhea, dysfunctional uterine bleeding, or unexplained infertility), and one-half are obese. Thus, only about one-third of classic cases have the full-blown clinical picture (Fig. 1). The laboratory diagnostic criteria for classic PCOS require biochemical evidence of hyperandrogenism with either a polycystic ovary by ultrasound or an increased serum level of luteinizing hormone (LH) or LH to follicle-stimulating hormone (FSH) ratio. These criteria have proven to not necessarily coincide (Fig. 2). Nonclassic and atypical polycystic ovary syndromeIn 1990, the National Institutes of Health (NIH) Conference on PCOS considered the implications of recent research findings for the diagnosis [2]. Fifty percent to 60% of those present concurred that the criteria for PCOS should consist of chronic anovulation with clinical or biochemical signs of hyperandrogenism that was not explained by other etiologies. This recognized the spectrum of the syndrome to include androgen excess in the absence of ultrasonographic and gonadotropic abnormalities (here termed nonclassic PCOS). NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author ManuscriptThe androgen excess of PCOS usually results from characteristic types of functional ovarian hyperandrogenism (FOH) or functional adrenal hyper-androgenism (FAH) [3,4]. FOH is gonadotropin-dependent excessive ovarian androgen production, and it occurs in most women with classic PCOS. It is also found in an equal number of hyperandrogenic women who do not meet the criteria for classic PCOS. It is characterized by 17-hydroxyprogesterone hyper-responsiveness to gonadotropin...

show abstract

Testosterone Measured by 10 Immunoassays and by Isotope-Dilution Gas Chromatography–Mass Spectrometry in Sera from 116 Men, Women, and Children

Cited by 570 publications

References 41 publications

Testosterone therapy increased muscle mass and lipid oxidation in aging men

Testosterone therapy increased muscle mass and lipid oxidation in aging men

Steroid measurement with LC–MS/MS in pediatric endocrinology

Polycystic Ovary Syndrome in Adolescence

Contact Info

Product

Resources

About